Medartis Holding AG (SIX: MED) held its 2026 Annual General Meeting (AGM) on April 23, 2026, at its headquarters in Basel, Switzerland, with strong shareholder participation. A total of 10,545,669 shares were represented, accounting for 77.4% of the total share capital, according to a company press release. All substantive proposals by the Board of Directors were approved with significant majorities, exceeding 90.9%.
Seven incumbent board members were re-elected with resounding support, each securing more than 93.8% of represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee. Chairman Marco Gadola will continue to lead the board, while Jennifer Dean decided not to stand for re-election after two years with Medartis. Damien Tappy and Marco Gadola were also confirmed as members of the Human Resources and Compensation Committee (HRCC).
Shareholders granted discharge to the board members for their governance during the 2025 term. The proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components, was approved through separate votes. The 2025 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement (99.2%) of represented shares, confirming Medartis' commitment to transparent ESG practices.
For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link. Medartis also confirmed upcoming investor and corporate calendar dates. On June 4, 2026, the company will host an Investor Visitor Day in Basel, held on the fringes of the FESSH Hand Surgery Congress. The event is open to institutional investors and will provide an opportunity to engage with management. The first-half 2026 results will be published on August 18, 2026, followed by the customary analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters in Basel.
The strong shareholder backing underscores confidence in Medartis' strategic direction and governance. The election of Yang Xu, who brings expertise in finance and audit, is seen as a move to strengthen oversight as the company continues to expand globally. Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures and joint replacement for upper and lower extremities as well as for the craniomaxillofacial region. The Group has manufacturing sites in Switzerland, the United States, Brazil, and France, employs approximately 1,400 individuals across 12 countries, and offers products in over 60 countries globally.
